Last reviewed · How we verify
Cipterbin Combined With Vinorelbine
Cipterbin combined with vinorelbine uses a dual approach: cipterbin inhibits tumor cell signaling while vinorelbine disrupts microtubule dynamics to arrest cell division.
Cipterbin combined with vinorelbine uses a dual approach: cipterbin inhibits tumor cell signaling while vinorelbine disrupts microtubule dynamics to arrest cell division. Used for Non-small cell lung cancer.
At a glance
| Generic name | Cipterbin Combined With Vinorelbine |
|---|---|
| Sponsor | Zhejiang Cancer Hospital |
| Drug class | Tyrosine kinase inhibitor combined with vinca alkaloid |
| Target | Multiple tyrosine kinases (cipterbin); tubulin (vinorelbine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Cipterbin is a tyrosine kinase inhibitor that targets growth factor signaling pathways in cancer cells. Vinorelbine is a semi-synthetic vinca alkaloid that binds to tubulin and prevents microtubule assembly, leading to mitotic arrest. The combination leverages complementary mechanisms to enhance cytotoxic effects against cancer cells.
Approved indications
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Fatigue
Key clinical trials
- Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (PHASE2)
- Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC (PHASE4)
- Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cipterbin Combined With Vinorelbine CI brief — competitive landscape report
- Cipterbin Combined With Vinorelbine updates RSS · CI watch RSS
- Zhejiang Cancer Hospital portfolio CI